Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 37 - Drugs for immunological or allergic disorders
Patents for A61P 37 - Drugs for immunological or allergic disorders (117,141)
03/2003
03/11/2003US6531479 Anti-cancer compounds
03/11/2003US6531474 Inhibitors of caspases
03/11/2003US6531473 Method of treatment using arylalkylpyridazinones
03/11/2003US6531313 Invasive bacterial vectors for expressing alphavirus replicons
03/11/2003US6531276 Using probes to determine duplex formation; use in diagnostic, prophylactic, and therapeutic applications
03/11/2003US6531140 Anti-irritant compositions containing a cyclic nucleotide
03/11/2003US6531139 Self-emulsifying formulation for lipophilic compounds
03/11/2003US6531138 Recombinant polypeptides and peptides, nucleic acids coding for the same and use of these polypetides and peptides in the diagnostic of tuberculosis
03/11/2003US6531129 Heparanase specific molecular probes and their use in research and medical applications
03/11/2003CA2264254C Phosphinic acid amides as matrix metalloprotease inhibitors
03/11/2003CA2121230C 1,3-dihydro-2h-imidazo(4,5-b) quinolin-2-one derivatives
03/10/2003CA2401358A1 Diacid-substituted heteroaryl derivatives as matrix metalloproteinase inhibitors
03/06/2003WO2003019146A2 High throughput screening assays using fatty acid synthetic enzymes
03/06/2003WO2003018836A2 Model of autoimmune disease and methods for identifying agents against autoimmune disease
03/06/2003WO2003018759A2 Phenylalanine ammonia lyase polypeptide and polynucleotide sequences and methods of obtaining and using same
03/06/2003WO2003018756A2 Methods for preparing purified prostaglandin e synthase
03/06/2003WO2003018640A2 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003WO2003018632A2 Epitope regions of a thyrotrophin (tsh) receptor, uses thereof and antibodies thereto
03/06/2003WO2003018619A2 Antimicrobial and anti-inflammatory peptides
03/06/2003WO2003018612A2 Extracellular messengers
03/06/2003WO2003018606A2 Casein derived peptides and uses thereof in therapy
03/06/2003WO2003018579A1 Alkyne-aryl phosphodiesterase-4 inhibitors
03/06/2003WO2003018576A1 New piperidinyl-morpholinyl derivatives as modulators of chemokine receptor activity
03/06/2003WO2003018566A1 New piperidinyl derivates as modulators of chemokine receptor activity
03/06/2003WO2003018556A1 Piperidine derivatives useful as modulators of chemokine receptor activity
03/06/2003WO2003018515A2 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003WO2003018052A1 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
03/06/2003WO2003018048A1 Use of hla class 1 soluble molecules to inhibit angiogenesis
03/06/2003WO2003018020A1 Jnk inhibitors
03/06/2003WO2003017947A2 Spontaneous emulsions containing cyclosporine
03/06/2003WO2003017935A2 Human antibodies specific for interleukin 15 (il-15)
03/06/2003WO2003002090B1 Immunopotentiator for mammary gland of dairy cows containing lactoferrin as an active ingredient
03/06/2003WO2002100844A3 Hiv protease inhibitors, compositions containing the same, their pharmaceutical uses and materials for their synthesis
03/06/2003WO2002094830A3 DIHYDROPYRROLO[1,2-A]INDOLE AND TETRAHYDROPYRIDO[1,2-a]-INDOLE DERIVATIVES AS PROSTAGLANDIN D2 RECEPTOR ANTAGONISTS
03/06/2003WO2002086069A3 Secreted proteins
03/06/2003WO2002085945A3 Vhh single heavy chain antibody and a method for its preparation in a mammal
03/06/2003WO2002085447A3 Microprojection array having a beneficial agent containing coating
03/06/2003WO2002072570A3 Non-imidazole compounds as histamine h3 antagonists
03/06/2003WO2002066516A3 Antibodies that bind both bcma and taci
03/06/2003WO2002064096A3 Methods of using pyrimidine-based antiviral agents
03/06/2003WO2002058681A8 Use of rhein for preparing a medicine for treating a high level of il-1
03/06/2003WO2002055507A8 1-dimercaptoalkylquinazolin-2,4(1h,3h)-diones as matrix metalloproteinase (mmp) inhibitors
03/06/2003WO2002047689A3 Use of cetirizine or efletirizine for preventing urticaria
03/06/2003WO2002034726A9 Pyrimidine-2,4,6-trione metalloproteinase inhibitors
03/06/2003WO2002028481A3 Methods of therapy for b-cell malignancies using antagonist anti-cd40 antibodies
03/06/2003WO2002022080A9 Enhanced first generation adenovirus vaccines expressing codon optimized hiv1-gag, pol, nef and modifications
03/06/2003WO2002020516A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the crystals and medicines containing the same as the active ingredient
03/06/2003WO2002012281A9 Molecular vaccine linking an endoplasmic reticulum chaperone polypeptide to an antigen
03/06/2003WO2002006478A8 Extracellular matrix protein
03/06/2003WO2001092304A3 Transporters and ion channels
03/06/2003WO2001080880A8 Apoptotic agents
03/06/2003WO2001074900A9 Nuclear factor kb inducing factor
03/06/2003WO2001066596A9 Human fgf-23 gene and gene expression products
03/06/2003US20030045721 Process for preparing anhydrous and hydrate forms of antihistaminic piperidine derivatives, polymorphs and pseudomorphs thereof
03/06/2003US20030045586 Use of amines
03/06/2003US20030045565 1-(pyrrolidin-1-ylmethyl)-3-(pyrrol-2-ylmethylidene)-2-indolinone derivatives
03/06/2003US20030045557 Thiadiazoles and oxadiazoles and their use as phosphodiesterase-7 inhibitors
03/06/2003US20030045556 Aryl-N-cyanoguanidines and methods related thereto
03/06/2003US20030045554 Such as 1-(2-thien-2'-yl- 2-oxoethyl)-3-((3-phenylmethyl) pyrazol-5-yl)pyridinium bromide for treating diseases caused by the accumulation of AGE (Advanced Glycation Endproducts); antidiabetic/ antiaging agents
03/06/2003US20030045552 Isoindole-imide compounds, compositions, and uses thereof
03/06/2003US20030045546 Anticancer agents
03/06/2003US20030045545 Immunomodulators, induce cytokine biosynthesis, and antineoplastic agents
03/06/2003US20030045533 Phosphodiesterase 4 inhibitors
03/06/2003US20030045521 Sulfohydroxamic acids and sulfohydroxamates and their use as MEK inhibitors
03/06/2003US20030045519 Treating allergy, allergy-induced airway responses, and congestion (e.g., nasal congestion)
03/06/2003US20030045516 Chemokine receptor antagonists and methods of use therefor
03/06/2003US20030045515 Cyanoguanidine I kappa B kinase inhibitors as antiproliferative agents for cancer treatment
03/06/2003US20030045505 Oligosaccharide having at least a D-galactose unit bound by an alpha (1-6) bond with a sucrose unit; second component is a molecule positively charged at physiological pH and that promotes pinocytosis or membrane penetration
03/06/2003US20030045490 Therapeutic antisense phosphodiesterase inhibitors
03/06/2003US20030045483 Novel substance having physiological activity, process for producing the same, and use
03/06/2003US20030045481 Use of specific amino acids reduces or prevents coloration attributable to a saccharide stabilizer; especially useful in pharmacologically active proteinaceous compositions
03/06/2003US20030045466 Calcium binding protein
03/06/2003US20030045460 Orally administered peptides to ameliorate atherosclerosis
03/06/2003US20030044975 Cytokine-binding domain for use in the treatment of asthma and thrombocytopenia
03/06/2003US20030044915 Method for preparing a polypeptide soluble in an aqueous solvent in the absence of detergent
03/06/2003US20030044898 Nucleotide sequences coding polypeptide for use in the treatment of asthma, parkinson's, heart defects, hypotension, urogenital and bone disorders
03/06/2003US20030044893 Nectin polypeptides, polynucleotides, methods of making and use thereof
03/06/2003US20030044768 PD-1, a receptor for B7-4, and uses therefor
03/06/2003US20030044464 Sustained-release, oral pharamaceutical forms of formulation
03/06/2003US20030044452 Composition for topical administration
03/06/2003US20030044446 A multilayered film comprising a first, water-soluble adhesive layer to be placed in contact with a mucosal surface and a second, water-erodible non-adhesive backing layer that controls residence time; drug delivery from mouth
03/06/2003US20030044425 Adjuvant complex composed of bacterial outer membrane protein proteosomes complexed to bacterial liposaccharide; immunogenic compositions, vaccines and immunotherapeutics
03/06/2003US20030044424 Novel immune enhancing compositions
03/06/2003US20030044406 Methods of preventing or treating inflammatory or autoimmune disorders by administering CD2 antagonists in combination with other prophylactic or therapeutic agents
03/06/2003US20030044352 Autoimmune disease, anticarcinogenic agents
03/06/2003CA2458924A1 Casein derived peptides and uses thereof in therapy
03/06/2003CA2458448A1 Spontaneous emulsions containing cyclosporine
03/06/2003CA2458445A1 Extracellular messengers
03/06/2003CA2458131A1 Jnk activation inhibitor
03/06/2003CA2457885A1 Antimicrobial and anti-inflammatory peptides
03/06/2003CA2457846A1 Use of heparinoid derivatives for treating and diagnosing diseases that can be treated by heparinoids
03/06/2003CA2457779A1 Moraxella (branhamella) catarrhalis polypeptides and corresponding dna fragments
03/06/2003CA2449515A1 Prime ring substituted thyroid receptor antagonists for the treatment of cardiac and metabolic disorders
03/06/2003CA2421499A1 Novel crystals of 1,3,4-oxadiazole derivative, process for producing the same and pharmaceutical agent containing the same as active ingredient
03/05/2003EP1288305A2 Plasma prekallikrein activation and kallikrein production assay
03/05/2003EP1288299A2 TRNA synthetase
03/05/2003EP1288298A2 TRNA synthetase from Staphylococcus aureus
03/05/2003EP1288224A1 Therapeutic peptide derivatives
03/05/2003EP1288223A1 Therapeutic peptide derivatives
03/05/2003EP1288206A1 Substituted benzenesulfonamide derivatives as prodrugs of COX-2 inhibitors
1 ... 737 738 739 740 741 742 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 ... 1172